SlideShare ist ein Scribd-Unternehmen logo
1 von 31
NICE Decision Outcomes Under the
Proposed Value Based Assessment
(VBA)
Martina Garau
PharmAccess Leaders Forum • 19 May 2014
Paris, France
Value Based Assessment in the UK 2
• Established in 1962
• Conduct research and provide consultancy services
on health economics and related policy issues that
affect health care and the life sciences industries
• Senior Leadership Team: Adrian Towse, Nancy Devlin, Jon
Sussex and Jorge Mestre-Ferrandiz; and a team with
diverse and complimentary expertise.
• Examples: value-based pricing for molecular diagnostics;
multi-criteria decision analysis for valuing orphan
medicines; using QALYs in cancer
About OHE
Value Based Assessment in the UK 3
• Context
• Key changes of NICE methods proposed in the value based
assessment (VBA) consultation:
• ICER threshold/ 'flexible' decision making
• Burden of illness
• Wider societal impact
• Other criteria
• Measuring absolute and proportional shortfall
• Illustrative examples
• Data required for shortfall measurements
• Summary points
Agenda
Value Based Assessment in the UK 4
• ‘Value based pricing’ (VBP) entered UK policy
language via the Office of Fair Trading's (OFT)
February 2007 report of its investigation into the
Pharmaceutical Price Regulation Scheme (PPRS)
• One key recommendation: replacement of profit
and price controls with 'VBP'
• Centralised price setting mechanism determined
(or at least heavily influenced) by HTA, assuming:
• value = incremental cost effectiveness, and
• an explicit threshold can be determined
History of value based pricing
Value Based Assessment in the UK 5
Andrew Lansley’s pre-election view, 2010
Value Based Assessment in the UK 6
1. Pharmacoeconomic
evaluation - QALYs
2. 'Burden of illness'
3. 'Therapeutic
innovation &
improvements'
4. 'Wider societal
benefits'
5. Combined via adjusted
£/QALY threshold
DH proposing 'VBP' for all new medicines
(December 2010)
December
2010
July 2011
Value Based Assessment in the UK 7
• Central role of NICE in value based
assessment (VBA)
• Consultation set out to amend the
current Guide to Methods of Technology
Appraisal
• ...to end in June 2014
Terms of reference to NICE
from DH (July 2013)
Value Based Assessment in the UK 8
HTA
• Manufacturer sets price then NICE accepts or rejects for
reimbursement at that price
• Life-extending treatments for patients with <2 years of
life expectancy may be eligible for an end-of-life premium
PPRS: 1 January 2014 until 31 Dec 2018
• Pre-agreed level of allowed growth rate of UK branded
medicine bill for each year of the scheme
• Payments in cash once the allowed growth rate is
exceeded
Current HTA processes and pricing
system
Distribution of NICE decisions
by year
NICE has become more binary in its decisions
Source: OHE Analysis
Distribution of NICE decisions for
orphan medicines
75% of orphans are for cancer
Source: OHE analysis
Orphan drugs are less likely to be recommended by NICE
Distribution of NICE decisions for cancer drugs:
before and after introduction of end-of -life
(EoL) criteria (2009)
Post-EoL era is associated with more cancer medicine rejections
(Note: not all cancer medicines qualify for EoL criteria)
Source: OHE analysis
Value Based Assessment in the UK 12
• Context
• Key changes of NICE methods proposed in the
value based assessment (VBA) consultation:
• ICER threshold/ 'flexible' decision making
• Burden of illness
• Wider societal impact
• Other criteria
• Measuring absolute and proportional shortfall
• Illustrative examples
• Data required for shortfall measurements
• Summary points
Agenda
Value Based Assessment in the UK 13
NICE’s current approach
£20,000 per QALY
£30,000 per QALY
£50,000 per QALY
Source: NICE Consultation Paper – Value Based Assessment of Health Technologies
Value Based Assessment in the UK 14
Proposed 'modifiers'
£20,000 per QALY
£50,000 per QALY
Source: NICE Consultation Paper – Value Based Assessment of Health Technologies
Value Based Assessment in the UK 15
• Current threshold: £20k to £30k with discretion
above that level (mainly based on end-of-life
criteria)
• Proposed threshold: £20k with discretion up to
£50k
• Maximum multiplier (now explicitly indicated) = 2.5
• No indication on how modifiers will be combined
• Only specified that their cumulative impact cannot
exceed 2.5
New 'flexible' decision making
Value Based Assessment in the UK 16
• Aim is to measure the severity of the condition suffered by
the patient population
• Measured using 'proportional QALY shortfall‘
=
𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙 𝑜𝑜𝑜𝑜 𝑄𝑄𝑄𝑄𝑄𝑄𝑄𝑄𝑄𝑄 𝑤𝑤𝑤𝑤𝑤𝑤 𝑤𝑤𝑤𝑤𝑤𝑤𝑤 𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 (𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 𝑎𝑎𝑎𝑎𝑎𝑎)
𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛 𝑜𝑜𝑜𝑜 𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟 𝑄𝑄𝑄𝑄𝑄𝑄𝑄𝑄𝑄𝑄 𝑓𝑓𝑓𝑓𝑓𝑓 ℎ𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 (𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔 𝑎𝑎𝑎𝑎𝑎𝑎)
• Recognises severity position of patients at end of life (EoL)
independently from age  proposal is to exclude EoL criteria
• Products that have greater than average proportional
shortfall will be assessed against a higher threshold
(multiplier > 1)
• No guidance for committee on how to apply burden measures
to threshold
Burden of illness (BoI)
Value Based Assessment in the UK 17
• No direct attempt to estimate wider economic impact of a
treatment (e.g. 'working days lost')
• Instead, NICE proposes to use 'absolute QALY shortfall'
as a proxy for patient’s reduced ability to contribute to
society
= 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙 𝑜𝑜𝑜𝑜 𝑄𝑄𝑄𝑄𝑄𝑄𝑄𝑄𝑄𝑄 𝑤𝑤𝑤𝑤𝑤𝑤 𝑤𝑤𝑤𝑤𝑤𝑤𝑤 𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 (𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔 𝑎𝑎𝑎𝑎𝑎𝑎)
• Products that have greater than average absolute shortfall
could face a threshold greater than £20k
• Again, no guidance as to how this will work in practice
Wider societal impact (WSI)
Value Based Assessment in the UK 18
• Context
• Key changes of NICE methods proposed in the value
based assessment (VBA) consultation:
• ICER threshold/ 'flexible' decision making
• Burden of illness
• Wider societal impact
• Other criteria
• Measuring absolute and proportional shortfall
• Illustrative examples
• Data required for shortfall measurements
• Summary points
Agenda
Value Based Assessment in the UK 19
• Absolute shortfall (AS)
• Captures that society cares about absolute loss of life and
quality of life
• Based on 'prospective health' (no value on previous health
experiences)
• Benefits younger populations who have a more QALYs to
lose sensitive to age
• Proportional shortfall (PS)
• Capable of recognising severity of illness in elderly
populations
• Gives weight to populations facing imminent death
• Contains elements of fair innings and prospective health
arguments
Absolute shortfall vs. proportional
shortfall
Value Based Assessment in the UK 20
Measuring absolute and
proportional shortfall (1)
Source: NICE Decision Support Unit critique of DH proposals for BoI
Value Based Assessment in the UK 21
Measuring absolute and
proportional shortfall (2)
• Total potential health (disease-free) going forward =
A+B+C+D
• Current health prospects (with disease) = D
• Absolute shortfall = health lost due to disease = total
potential health minus current health prospects = A+B+C
• Proportional shortfall = ratio of health lost to total potential
health = (A+B+C) / (A+B+C+D)
Value Based Assessment in the UK 22
• TA 178: Bevacizumab, sorafenib, sunitinib and temsirolimus for
treatment of advanced renal cell carcinoma
• Average age of patient = 60
• Expected QALYs without disease = 20.5
• Expected QALYs with disease = 1.24
– Met EoL criteria
• Absolute shortfall = 20.5 – 1.24 = 19.26
• Proportional shortfall = 19.26/20.5 = 94%
• Both AS and PS significantly greater than average (2.1; 9%) 
implies drug would be assessed against ICER threshold > £20k
• Proportional shortfall could replicate EoL effect
Illustrative example 1
Source: NICE illustrative table
http://www.nice.org.uk/getinvolved/currentniceconsultations/MethodsOfTechnologyAppraisalConsultation2014.jsp
Value Based Assessment in the UK 23
• TA 217: Donepezil, galantamine, rivastigmine and memantine
for the treatment of Alzheimer’s disease
• Average age of patient = 77
• Expected QALYs without disease = 8.7
• Expected QALYs with disease = 1.58
• Absolute shortfall = 8.7 – 1.58 = 7.09
• Proportional shortfall = 7.09/8.7 = 82%
• Again, both AS and PS significantly greater than average (2.1;
9%)  implies drug would be assessed against ICER threshold
> £20k
• However, absolute shortfall is lower than previous example,
given age of patients
Illustrative example 2
Source: NICE illustrative table
http://www.nice.org.uk/getinvolved/currentniceconsultations/MethodsOfTechnologyAppraisalConsultation2014.jsp
Value Based Assessment in the UK 24
• TA 254: Fingolimod for the treatment of relapsing remitting
multiple sclerosis
• Average age of patient = 37
• Expected QALYs without disease = 40.7
• Expected QALYs with disease = 3.99
• Absolute shortfall = 40.7 – 3.99 = 36.71
• Proportional shortfall = 36.71/40.7 = 90%
• Both AS and PS very high relative to average  implies drug would
be assessed against ICER threshold > £20k
• AS particularly high – reflects young average age of patients and
large health loss with disease
Illustrative example 3
Source: NICE illustrative table
http://www.nice.org.uk/getinvolved/currentniceconsultations/MethodsOfTechnologyAppraisalConsultation2014.jsp
Value Based Assessment in the UK 25
• TA 278: Omalizumab for treatment of severe asthma
• Average age of patient = 43
• Expected QALYs without disease = 34.83
• Expected QALYs with disease = 25.31
• Absolute shortfall = 34.83 - 25.31 = 9.52
• Proportional shortfall = 9.52/34.83 = 27%
• Again, both AS and PS greater than average (2.1, 9%)
but PS lower level than previous examples
Illustrative example 4
Source: NICE illustrative table
http://www.nice.org.uk/getinvolved/currentniceconsultations/MethodsOfTechnologyAppraisalConsultation2014.jsp
Value Based Assessment in the UK 26
Data required for shortfall
measurements
• DH has calculated BoI for different conditions from a reference
dataset developed by the University of York
• This presents BoI by the three digit ICD-10 code, aggregated
across 16 age/gender categories
• Given the broad level of aggregation within the reference dataset,
there could be different levels of severity for which it would be
important to capture the appropriate BoI
• In technology appraisals, it will be appropriate for the company to
present the BoI for the specific patient population for the product
being appraised
Value Based Assessment in the UK 27
• Uncertainty around incremental cost effectiveness
ratio (ICER):
• Penalties for uncertainty around the ICER now only
apply for routine use and where ICER is 'very
uncertain' rather than 'less certain'
• Health-related quality of life (HRQoL) inadequately
captured:
• No changes proposed
• Innovative nature of technology:
• Now includes reference to 'a step change in the
management of a condition'
• Non-health objectives of the NHS:
• No changes proposed
Other modifiers
Value Based Assessment in the UK 28
• Cost savings outside the NHS and non-health
benefits (e.g. productivity) can now be
considered even when not specifically requested
by the Department of Health in non-reference
case
Other changes to the methods
guide
Value Based Assessment in the UK 29
• EoL criteria replaced by BoI
• Proposed threshold = £20k, with discretion up to £50k for products
that qualify for modifiers
• No guidance on BoI and WSI weights
• No guidance on how other factors will be quantified and
aggregated
• It is likely that NICE will continue adopting a deliberative,
rather than an algorithmic, approach to making decisions
• An evolutionary, not revolutionary change
• For most products, outcomes will probably be similar to those
under the old system
Summary of key points
Value Based Assessment in the UK 30
Paul Barnsley for his work on absolute and proportional shortfall (see OHE
note on the NICE website)
Acknowledgements
Value Based Assessment in the UK 31
About OHE
To enquire about additional information and analyses, please contact Martina Garau at
mgarau@ohe.org
To keep up with the latest news and research, subscribe to our blog, OHE News.
Follow us on Twitter @OHENews, LinkedIn and SlideShare.
The Office of Health Economics is a research and consulting organisation that has been
providing specialised research, analysis and expertise on a range of health care and life
sciences issues and topics for more than 50 years.
OHE’s publications may be downloaded free of charge for registered users of its
website.
Office of Health Economics
Southside, 7th Floor
105 Victoria Street
London SW1E 6QT
United Kingdom
+44 20 7747 8850
www.ohe.org

Weitere ähnliche Inhalte

Was ist angesagt?

Innovative Pricing and Reimbursement Schemes - The Why, What, Which & How
Innovative Pricing and Reimbursement Schemes - The Why, What, Which & HowInnovative Pricing and Reimbursement Schemes - The Why, What, Which & How
Innovative Pricing and Reimbursement Schemes - The Why, What, Which & HowPAREXEL International
 
Establishing a Reasonable Price for an Orphan Drug
Establishing a Reasonable Price for an Orphan DrugEstablishing a Reasonable Price for an Orphan Drug
Establishing a Reasonable Price for an Orphan DrugOffice of Health Economics
 
Leveraging Imaging and Wearable Technology For Agile Clinical Trials
Leveraging Imaging and Wearable Technology For Agile Clinical TrialsLeveraging Imaging and Wearable Technology For Agile Clinical Trials
Leveraging Imaging and Wearable Technology For Agile Clinical TrialsPAREXEL International
 
Presentation - New Business Models for Antibiotics: Where Are We Now? 16 Marc...
Presentation - New Business Models for Antibiotics: Where Are We Now? 16 Marc...Presentation - New Business Models for Antibiotics: Where Are We Now? 16 Marc...
Presentation - New Business Models for Antibiotics: Where Are We Now? 16 Marc...Office of Health Economics
 
Presentation: Global pharmacovigilance networks - A regulator's
Presentation: Global pharmacovigilance networks - A regulator'sPresentation: Global pharmacovigilance networks - A regulator's
Presentation: Global pharmacovigilance networks - A regulator'sTGA Australia
 
Pharmacovigilance in India -Dr. Kamlesh Patel for global bioclinical 2012
Pharmacovigilance in India -Dr. Kamlesh Patel for global bioclinical 2012Pharmacovigilance in India -Dr. Kamlesh Patel for global bioclinical 2012
Pharmacovigilance in India -Dr. Kamlesh Patel for global bioclinical 2012kamynevy
 
Exploring Ways to Enhance Evidence Generation & Communication Planning
Exploring Ways to Enhance Evidence Generation & Communication PlanningExploring Ways to Enhance Evidence Generation & Communication Planning
Exploring Ways to Enhance Evidence Generation & Communication PlanningPAREXEL International
 
The Value of Targeted Sequencing in Advanced Cancer: DCE to Elicit the Public...
The Value of Targeted Sequencing in Advanced Cancer: DCE to Elicit the Public...The Value of Targeted Sequencing in Advanced Cancer: DCE to Elicit the Public...
The Value of Targeted Sequencing in Advanced Cancer: DCE to Elicit the Public...Office of Health Economics
 
pharmacovigilance pdf (1)
pharmacovigilance pdf (1)pharmacovigilance pdf (1)
pharmacovigilance pdf (1)Prasad Bhat
 
Understanding Regulatory and Payer Requirements Throughout Commercialization
Understanding Regulatory and Payer Requirements Throughout CommercializationUnderstanding Regulatory and Payer Requirements Throughout Commercialization
Understanding Regulatory and Payer Requirements Throughout CommercializationPAREXEL International
 
Incorporating Life-cycle Price Modelling into Pharmaceutical Cost-effectivene...
Incorporating Life-cycle Price Modelling into Pharmaceutical Cost-effectivene...Incorporating Life-cycle Price Modelling into Pharmaceutical Cost-effectivene...
Incorporating Life-cycle Price Modelling into Pharmaceutical Cost-effectivene...Office of Health Economics
 
Presentation by Paula Lorgelly - Beyond QALYs: A Quantum Leap Forward or a Le...
Presentation by Paula Lorgelly - Beyond QALYs: A Quantum Leap Forward or a Le...Presentation by Paula Lorgelly - Beyond QALYs: A Quantum Leap Forward or a Le...
Presentation by Paula Lorgelly - Beyond QALYs: A Quantum Leap Forward or a Le...Office of Health Economics
 
Complementary medicines MMDR reforms: Assessment pathways
Complementary medicines MMDR reforms: Assessment pathwaysComplementary medicines MMDR reforms: Assessment pathways
Complementary medicines MMDR reforms: Assessment pathwaysTGA Australia
 
Edith Frénoy, 2nd Health Innovation Conference
Edith Frénoy, 2nd Health Innovation ConferenceEdith Frénoy, 2nd Health Innovation Conference
Edith Frénoy, 2nd Health Innovation ConferenceStarttech Ventures
 
FDA Initiatives Under The 21st Century Cures Act
FDA Initiatives Under The 21st Century Cures ActFDA Initiatives Under The 21st Century Cures Act
FDA Initiatives Under The 21st Century Cures ActPAREXEL International
 
Complex Innovative Trial Designs
Complex Innovative Trial DesignsComplex Innovative Trial Designs
Complex Innovative Trial DesignsFrancois MAIGNEN
 
Development Considerations Comparing Major Markets Including US, EU, Japan an...
Development Considerations Comparing Major Markets Including US, EU, Japan an...Development Considerations Comparing Major Markets Including US, EU, Japan an...
Development Considerations Comparing Major Markets Including US, EU, Japan an...PAREXEL International
 
Presentation: Overview - Regulatory Obligations Seminar
Presentation: Overview - Regulatory Obligations SeminarPresentation: Overview - Regulatory Obligations Seminar
Presentation: Overview - Regulatory Obligations SeminarTGA Australia
 

Was ist angesagt? (20)

Innovative Pricing and Reimbursement Schemes - The Why, What, Which & How
Innovative Pricing and Reimbursement Schemes - The Why, What, Which & HowInnovative Pricing and Reimbursement Schemes - The Why, What, Which & How
Innovative Pricing and Reimbursement Schemes - The Why, What, Which & How
 
HTA in France
HTA in FranceHTA in France
HTA in France
 
Establishing a Reasonable Price for an Orphan Drug
Establishing a Reasonable Price for an Orphan DrugEstablishing a Reasonable Price for an Orphan Drug
Establishing a Reasonable Price for an Orphan Drug
 
Leveraging Imaging and Wearable Technology For Agile Clinical Trials
Leveraging Imaging and Wearable Technology For Agile Clinical TrialsLeveraging Imaging and Wearable Technology For Agile Clinical Trials
Leveraging Imaging and Wearable Technology For Agile Clinical Trials
 
Presentation - New Business Models for Antibiotics: Where Are We Now? 16 Marc...
Presentation - New Business Models for Antibiotics: Where Are We Now? 16 Marc...Presentation - New Business Models for Antibiotics: Where Are We Now? 16 Marc...
Presentation - New Business Models for Antibiotics: Where Are We Now? 16 Marc...
 
Presentation: Global pharmacovigilance networks - A regulator's
Presentation: Global pharmacovigilance networks - A regulator'sPresentation: Global pharmacovigilance networks - A regulator's
Presentation: Global pharmacovigilance networks - A regulator's
 
Pharmacovigilance in India -Dr. Kamlesh Patel for global bioclinical 2012
Pharmacovigilance in India -Dr. Kamlesh Patel for global bioclinical 2012Pharmacovigilance in India -Dr. Kamlesh Patel for global bioclinical 2012
Pharmacovigilance in India -Dr. Kamlesh Patel for global bioclinical 2012
 
Exploring Ways to Enhance Evidence Generation & Communication Planning
Exploring Ways to Enhance Evidence Generation & Communication PlanningExploring Ways to Enhance Evidence Generation & Communication Planning
Exploring Ways to Enhance Evidence Generation & Communication Planning
 
The Value of Targeted Sequencing in Advanced Cancer: DCE to Elicit the Public...
The Value of Targeted Sequencing in Advanced Cancer: DCE to Elicit the Public...The Value of Targeted Sequencing in Advanced Cancer: DCE to Elicit the Public...
The Value of Targeted Sequencing in Advanced Cancer: DCE to Elicit the Public...
 
Day 2: Panel 4 Slides (Biosimilars)
Day 2: Panel 4 Slides (Biosimilars) Day 2: Panel 4 Slides (Biosimilars)
Day 2: Panel 4 Slides (Biosimilars)
 
pharmacovigilance pdf (1)
pharmacovigilance pdf (1)pharmacovigilance pdf (1)
pharmacovigilance pdf (1)
 
Understanding Regulatory and Payer Requirements Throughout Commercialization
Understanding Regulatory and Payer Requirements Throughout CommercializationUnderstanding Regulatory and Payer Requirements Throughout Commercialization
Understanding Regulatory and Payer Requirements Throughout Commercialization
 
Incorporating Life-cycle Price Modelling into Pharmaceutical Cost-effectivene...
Incorporating Life-cycle Price Modelling into Pharmaceutical Cost-effectivene...Incorporating Life-cycle Price Modelling into Pharmaceutical Cost-effectivene...
Incorporating Life-cycle Price Modelling into Pharmaceutical Cost-effectivene...
 
Presentation by Paula Lorgelly - Beyond QALYs: A Quantum Leap Forward or a Le...
Presentation by Paula Lorgelly - Beyond QALYs: A Quantum Leap Forward or a Le...Presentation by Paula Lorgelly - Beyond QALYs: A Quantum Leap Forward or a Le...
Presentation by Paula Lorgelly - Beyond QALYs: A Quantum Leap Forward or a Le...
 
Complementary medicines MMDR reforms: Assessment pathways
Complementary medicines MMDR reforms: Assessment pathwaysComplementary medicines MMDR reforms: Assessment pathways
Complementary medicines MMDR reforms: Assessment pathways
 
Edith Frénoy, 2nd Health Innovation Conference
Edith Frénoy, 2nd Health Innovation ConferenceEdith Frénoy, 2nd Health Innovation Conference
Edith Frénoy, 2nd Health Innovation Conference
 
FDA Initiatives Under The 21st Century Cures Act
FDA Initiatives Under The 21st Century Cures ActFDA Initiatives Under The 21st Century Cures Act
FDA Initiatives Under The 21st Century Cures Act
 
Complex Innovative Trial Designs
Complex Innovative Trial DesignsComplex Innovative Trial Designs
Complex Innovative Trial Designs
 
Development Considerations Comparing Major Markets Including US, EU, Japan an...
Development Considerations Comparing Major Markets Including US, EU, Japan an...Development Considerations Comparing Major Markets Including US, EU, Japan an...
Development Considerations Comparing Major Markets Including US, EU, Japan an...
 
Presentation: Overview - Regulatory Obligations Seminar
Presentation: Overview - Regulatory Obligations SeminarPresentation: Overview - Regulatory Obligations Seminar
Presentation: Overview - Regulatory Obligations Seminar
 

Ähnlich wie NICE Decision Outcomes Under the Proposed Valued Based Assessment

Health Technology Assessment: Comparison between UK and Canada Processes by D...
Health Technology Assessment: Comparison between UK and Canada Processes by D...Health Technology Assessment: Comparison between UK and Canada Processes by D...
Health Technology Assessment: Comparison between UK and Canada Processes by D...Dr. Tayaba Khan
 
ISPOR Special Task Force on US Value Frameworks: A Non-US Perspective
ISPOR Special Task Force on US Value Frameworks: A Non-US PerspectiveISPOR Special Task Force on US Value Frameworks: A Non-US Perspective
ISPOR Special Task Force on US Value Frameworks: A Non-US PerspectiveOffice of Health Economics
 
Translational Genomics_Health economic evaluation
Translational Genomics_Health economic evaluationTranslational Genomics_Health economic evaluation
Translational Genomics_Health economic evaluationKirsten van Nimwegen
 
Eliciting societal preference for burden of illness, therapeutic improvement ...
Eliciting societal preference for burden of illness, therapeutic improvement ...Eliciting societal preference for burden of illness, therapeutic improvement ...
Eliciting societal preference for burden of illness, therapeutic improvement ...John Brazier
 
An introduction to using cost-effectiveness analysis to inform spending decis...
An introduction to using cost-effectiveness analysis to inform spending decis...An introduction to using cost-effectiveness analysis to inform spending decis...
An introduction to using cost-effectiveness analysis to inform spending decis...Carmen Figueroa
 
Comparative Effectiveness: UCSF East Africa Global Health -Kisumu 2014
Comparative Effectiveness: UCSF East Africa Global Health -Kisumu 2014Comparative Effectiveness: UCSF East Africa Global Health -Kisumu 2014
Comparative Effectiveness: UCSF East Africa Global Health -Kisumu 2014GlobalResearchUCSF
 
Establishing a Fair Price for an Orphan Drug by Mikel Berdud et al.
Establishing a Fair Price for an Orphan Drug by Mikel Berdud et al.Establishing a Fair Price for an Orphan Drug by Mikel Berdud et al.
Establishing a Fair Price for an Orphan Drug by Mikel Berdud et al.Office of Health Economics
 
Day 1: 2:45pm- 4:00pm Panel Slides (Nov 18) Access to Innovation Conference 2019
Day 1: 2:45pm- 4:00pm Panel Slides (Nov 18) Access to Innovation Conference 2019Day 1: 2:45pm- 4:00pm Panel Slides (Nov 18) Access to Innovation Conference 2019
Day 1: 2:45pm- 4:00pm Panel Slides (Nov 18) Access to Innovation Conference 2019Canadian Organization for Rare Disorders
 
Population Health Management PHM MLCSU huddle
Population Health Management PHM MLCSU huddlePopulation Health Management PHM MLCSU huddle
Population Health Management PHM MLCSU huddleMatthew Grek
 
The Cost of PH - How Do We Manage This?
The Cost of PH - How Do We Manage This? The Cost of PH - How Do We Manage This?
The Cost of PH - How Do We Manage This? Duke Heart
 
Improving Methods and Processes for Assessing Codependent Technologies
Improving Methods and Processes for Assessing Codependent TechnologiesImproving Methods and Processes for Assessing Codependent Technologies
Improving Methods and Processes for Assessing Codependent TechnologiesOffice of Health Economics
 
Modeling the cost effectiveness of two big league pay-for-performance policies
Modeling the cost effectiveness of two big league pay-for-performance policiesModeling the cost effectiveness of two big league pay-for-performance policies
Modeling the cost effectiveness of two big league pay-for-performance policiescheweb1
 
Hospital Concentration and Patients Outcomes in the NHS: New Research
Hospital Concentration and Patients Outcomes in the NHS: New ResearchHospital Concentration and Patients Outcomes in the NHS: New Research
Hospital Concentration and Patients Outcomes in the NHS: New ResearchOffice of Health Economics
 
2 gf h econ cost effectivness and roi
2 gf h econ cost effectivness and roi2 gf h econ cost effectivness and roi
2 gf h econ cost effectivness and roiGreg Fell
 
Pharmacoeconomics Cost utility analysis
Pharmacoeconomics Cost utility analysisPharmacoeconomics Cost utility analysis
Pharmacoeconomics Cost utility analysisMohammed Mohammed
 

Ähnlich wie NICE Decision Outcomes Under the Proposed Valued Based Assessment (20)

Health Technology Assessment: Comparison between UK and Canada Processes by D...
Health Technology Assessment: Comparison between UK and Canada Processes by D...Health Technology Assessment: Comparison between UK and Canada Processes by D...
Health Technology Assessment: Comparison between UK and Canada Processes by D...
 
ISPOR Special Task Force on US Value Frameworks: A Non-US Perspective
ISPOR Special Task Force on US Value Frameworks: A Non-US PerspectiveISPOR Special Task Force on US Value Frameworks: A Non-US Perspective
ISPOR Special Task Force on US Value Frameworks: A Non-US Perspective
 
Claire Hulme
Claire HulmeClaire Hulme
Claire Hulme
 
Translational Genomics_Health economic evaluation
Translational Genomics_Health economic evaluationTranslational Genomics_Health economic evaluation
Translational Genomics_Health economic evaluation
 
Reflections_on_VBP_AKT_June2015
Reflections_on_VBP_AKT_June2015Reflections_on_VBP_AKT_June2015
Reflections_on_VBP_AKT_June2015
 
Eliciting societal preference for burden of illness, therapeutic improvement ...
Eliciting societal preference for burden of illness, therapeutic improvement ...Eliciting societal preference for burden of illness, therapeutic improvement ...
Eliciting societal preference for burden of illness, therapeutic improvement ...
 
An introduction to using cost-effectiveness analysis to inform spending decis...
An introduction to using cost-effectiveness analysis to inform spending decis...An introduction to using cost-effectiveness analysis to inform spending decis...
An introduction to using cost-effectiveness analysis to inform spending decis...
 
Factors Influencing Decisions by NICE
Factors Influencing Decisions by NICEFactors Influencing Decisions by NICE
Factors Influencing Decisions by NICE
 
1410 prof james raftery nhc2015
1410 prof james raftery nhc20151410 prof james raftery nhc2015
1410 prof james raftery nhc2015
 
Comparative Effectiveness: UCSF East Africa Global Health -Kisumu 2014
Comparative Effectiveness: UCSF East Africa Global Health -Kisumu 2014Comparative Effectiveness: UCSF East Africa Global Health -Kisumu 2014
Comparative Effectiveness: UCSF East Africa Global Health -Kisumu 2014
 
Establishing a Fair Price for an Orphan Drug by Mikel Berdud et al.
Establishing a Fair Price for an Orphan Drug by Mikel Berdud et al.Establishing a Fair Price for an Orphan Drug by Mikel Berdud et al.
Establishing a Fair Price for an Orphan Drug by Mikel Berdud et al.
 
Day 1: 2:45pm- 4:00pm Panel Slides (Nov 18) Access to Innovation Conference 2019
Day 1: 2:45pm- 4:00pm Panel Slides (Nov 18) Access to Innovation Conference 2019Day 1: 2:45pm- 4:00pm Panel Slides (Nov 18) Access to Innovation Conference 2019
Day 1: 2:45pm- 4:00pm Panel Slides (Nov 18) Access to Innovation Conference 2019
 
Population Health Management PHM MLCSU huddle
Population Health Management PHM MLCSU huddlePopulation Health Management PHM MLCSU huddle
Population Health Management PHM MLCSU huddle
 
New Medicine Evaluation, Scottish Medicines Consortium
New Medicine Evaluation, Scottish Medicines ConsortiumNew Medicine Evaluation, Scottish Medicines Consortium
New Medicine Evaluation, Scottish Medicines Consortium
 
The Cost of PH - How Do We Manage This?
The Cost of PH - How Do We Manage This? The Cost of PH - How Do We Manage This?
The Cost of PH - How Do We Manage This?
 
Improving Methods and Processes for Assessing Codependent Technologies
Improving Methods and Processes for Assessing Codependent TechnologiesImproving Methods and Processes for Assessing Codependent Technologies
Improving Methods and Processes for Assessing Codependent Technologies
 
Modeling the cost effectiveness of two big league pay-for-performance policies
Modeling the cost effectiveness of two big league pay-for-performance policiesModeling the cost effectiveness of two big league pay-for-performance policies
Modeling the cost effectiveness of two big league pay-for-performance policies
 
Hospital Concentration and Patients Outcomes in the NHS: New Research
Hospital Concentration and Patients Outcomes in the NHS: New ResearchHospital Concentration and Patients Outcomes in the NHS: New Research
Hospital Concentration and Patients Outcomes in the NHS: New Research
 
2 gf h econ cost effectivness and roi
2 gf h econ cost effectivness and roi2 gf h econ cost effectivness and roi
2 gf h econ cost effectivness and roi
 
Pharmacoeconomics Cost utility analysis
Pharmacoeconomics Cost utility analysisPharmacoeconomics Cost utility analysis
Pharmacoeconomics Cost utility analysis
 

Mehr von Office of Health Economics

OHE presents at G20 AMR-R&D meeting in Paris - Adrian Towse
OHE presents at G20 AMR-R&D meeting in Paris - Adrian TowseOHE presents at G20 AMR-R&D meeting in Paris - Adrian Towse
OHE presents at G20 AMR-R&D meeting in Paris - Adrian TowseOffice of Health Economics
 
Pricing in emerging markets: options to get value for money - Adrian Towse
Pricing in emerging markets: options to get value for money - Adrian TowsePricing in emerging markets: options to get value for money - Adrian Towse
Pricing in emerging markets: options to get value for money - Adrian TowseOffice of Health Economics
 
% GDP spending in UK, G5 countries and OECD upper middle income countries. W...
% GDP spending in UK, G5 countries and OECD upper middle income countries.  W...% GDP spending in UK, G5 countries and OECD upper middle income countries.  W...
% GDP spending in UK, G5 countries and OECD upper middle income countries. W...Office of Health Economics
 
The role of real world data and evidence in building a sustainable & efficien...
The role of real world data and evidence in building a sustainable & efficien...The role of real world data and evidence in building a sustainable & efficien...
The role of real world data and evidence in building a sustainable & efficien...Office of Health Economics
 
ISPOR Education Symposium- Go where the money is
ISPOR Education Symposium- Go where the money isISPOR Education Symposium- Go where the money is
ISPOR Education Symposium- Go where the money isOffice of Health Economics
 
Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...
Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...
Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...Office of Health Economics
 
IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY?
 IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY? IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY?
IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY?Office of Health Economics
 
Understanding what aspects of health and quality of life are important to people
Understanding what aspects of health and quality of life are important to peopleUnderstanding what aspects of health and quality of life are important to people
Understanding what aspects of health and quality of life are important to peopleOffice of Health Economics
 
Novel approaches for valuing health at the end of life
Novel approaches for valuing health at the end of lifeNovel approaches for valuing health at the end of life
Novel approaches for valuing health at the end of lifeOffice of Health Economics
 
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...Office of Health Economics
 
HTA and payment mechanisms for new drugs to tackle AMR
HTA and payment mechanisms for new drugs to tackle AMRHTA and payment mechanisms for new drugs to tackle AMR
HTA and payment mechanisms for new drugs to tackle AMROffice of Health Economics
 
Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...
Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...
Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...Office of Health Economics
 
Pay for Performance for Specialised Care in England
Pay for Performance for Specialised Care in EnglandPay for Performance for Specialised Care in England
Pay for Performance for Specialised Care in EnglandOffice of Health Economics
 
Real option value drugs: is it really an option?
Real option value drugs: is it really an option?Real option value drugs: is it really an option?
Real option value drugs: is it really an option?Office of Health Economics
 
MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...
MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...
MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...Office of Health Economics
 
Lies, Damned Lies and Cost-Effectiveness: Open-Source Models
Lies, Damned Lies and Cost-Effectiveness: Open-Source ModelsLies, Damned Lies and Cost-Effectiveness: Open-Source Models
Lies, Damned Lies and Cost-Effectiveness: Open-Source ModelsOffice of Health Economics
 

Mehr von Office of Health Economics (20)

Annual lecture
Annual lecture Annual lecture
Annual lecture
 
Devlin ispor 2020 issues panel 20.05.20
Devlin ispor 2020 issues panel 20.05.20 Devlin ispor 2020 issues panel 20.05.20
Devlin ispor 2020 issues panel 20.05.20
 
Towse cgd price transparency seminar
Towse cgd price transparency seminarTowse cgd price transparency seminar
Towse cgd price transparency seminar
 
OHE presents at G20 AMR-R&D meeting in Paris - Adrian Towse
OHE presents at G20 AMR-R&D meeting in Paris - Adrian TowseOHE presents at G20 AMR-R&D meeting in Paris - Adrian Towse
OHE presents at G20 AMR-R&D meeting in Paris - Adrian Towse
 
Pricing in emerging markets: options to get value for money - Adrian Towse
Pricing in emerging markets: options to get value for money - Adrian TowsePricing in emerging markets: options to get value for money - Adrian Towse
Pricing in emerging markets: options to get value for money - Adrian Towse
 
% GDP spending in UK, G5 countries and OECD upper middle income countries. W...
% GDP spending in UK, G5 countries and OECD upper middle income countries.  W...% GDP spending in UK, G5 countries and OECD upper middle income countries.  W...
% GDP spending in UK, G5 countries and OECD upper middle income countries. W...
 
The role of real world data and evidence in building a sustainable & efficien...
The role of real world data and evidence in building a sustainable & efficien...The role of real world data and evidence in building a sustainable & efficien...
The role of real world data and evidence in building a sustainable & efficien...
 
ISPOR Education Symposium- Go where the money is
ISPOR Education Symposium- Go where the money isISPOR Education Symposium- Go where the money is
ISPOR Education Symposium- Go where the money is
 
Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...
Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...
Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...
 
IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY?
 IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY? IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY?
IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY?
 
Ispor 2019 poster - Patricia Cubi-Molla
Ispor 2019 poster - Patricia Cubi-MollaIspor 2019 poster - Patricia Cubi-Molla
Ispor 2019 poster - Patricia Cubi-Molla
 
Understanding what aspects of health and quality of life are important to people
Understanding what aspects of health and quality of life are important to peopleUnderstanding what aspects of health and quality of life are important to people
Understanding what aspects of health and quality of life are important to people
 
Novel approaches for valuing health at the end of life
Novel approaches for valuing health at the end of lifeNovel approaches for valuing health at the end of life
Novel approaches for valuing health at the end of life
 
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
 
HTA and payment mechanisms for new drugs to tackle AMR
HTA and payment mechanisms for new drugs to tackle AMRHTA and payment mechanisms for new drugs to tackle AMR
HTA and payment mechanisms for new drugs to tackle AMR
 
Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...
Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...
Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...
 
Pay for Performance for Specialised Care in England
Pay for Performance for Specialised Care in EnglandPay for Performance for Specialised Care in England
Pay for Performance for Specialised Care in England
 
Real option value drugs: is it really an option?
Real option value drugs: is it really an option?Real option value drugs: is it really an option?
Real option value drugs: is it really an option?
 
MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...
MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...
MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...
 
Lies, Damned Lies and Cost-Effectiveness: Open-Source Models
Lies, Damned Lies and Cost-Effectiveness: Open-Source ModelsLies, Damned Lies and Cost-Effectiveness: Open-Source Models
Lies, Damned Lies and Cost-Effectiveness: Open-Source Models
 

Kürzlich hochgeladen

TEST BANK For Neonatal and Pediatric Respiratory Care, 6th Edition by Brian K...
TEST BANK For Neonatal and Pediatric Respiratory Care, 6th Edition by Brian K...TEST BANK For Neonatal and Pediatric Respiratory Care, 6th Edition by Brian K...
TEST BANK For Neonatal and Pediatric Respiratory Care, 6th Edition by Brian K...mwangimwangi222
 
ARTHRITIS.pptx Prepared by monika gopal Tutor
ARTHRITIS.pptx Prepared  by monika gopal TutorARTHRITIS.pptx Prepared  by monika gopal Tutor
ARTHRITIS.pptx Prepared by monika gopal TutorNehaKewat
 
LARYNGEAL CANCER.pptx Prepared by Neha Kewat
LARYNGEAL CANCER.pptx  Prepared by Neha KewatLARYNGEAL CANCER.pptx  Prepared by Neha Kewat
LARYNGEAL CANCER.pptx Prepared by Neha KewatNehaKewat
 
LEUKODYSTROPHY FINAL.pptx sms medical jaipur
LEUKODYSTROPHY FINAL.pptx sms medical jaipurLEUKODYSTROPHY FINAL.pptx sms medical jaipur
LEUKODYSTROPHY FINAL.pptx sms medical jaipurdineshdandia
 
FINAL PROJECT IN EMPOWERMENT TECHNOLOGIES 11
FINAL PROJECT IN EMPOWERMENT TECHNOLOGIES  11FINAL PROJECT IN EMPOWERMENT TECHNOLOGIES  11
FINAL PROJECT IN EMPOWERMENT TECHNOLOGIES 11crzljavier
 
Toothpaste for bleeding gums and sensitive teeth. Teeth whitening, Mouthwash....
Toothpaste for bleeding gums and sensitive teeth. Teeth whitening, Mouthwash....Toothpaste for bleeding gums and sensitive teeth. Teeth whitening, Mouthwash....
Toothpaste for bleeding gums and sensitive teeth. Teeth whitening, Mouthwash....sharyurangari111
 
Introduction to Evaluation and Skin Benefits
Introduction to Evaluation and Skin BenefitsIntroduction to Evaluation and Skin Benefits
Introduction to Evaluation and Skin Benefitssahilgabhane29
 
EYE CANCER.pptx prepared by Neha kewat digital learning
EYE CANCER.pptx prepared by  Neha kewat digital learningEYE CANCER.pptx prepared by  Neha kewat digital learning
EYE CANCER.pptx prepared by Neha kewat digital learningNehaKewat
 
Assisted Living Care Residency - PapayaCare
Assisted Living Care Residency - PapayaCareAssisted Living Care Residency - PapayaCare
Assisted Living Care Residency - PapayaCareratilalthakkar704
 
Eating Disorders in Athletes I Sports Psychology
Eating Disorders in Athletes I Sports PsychologyEating Disorders in Athletes I Sports Psychology
Eating Disorders in Athletes I Sports Psychologyshantisphysio
 
Presentation on COUNSELING. 1ST YEAR GNM ,COMMUNITY HEALTH NURSING
Presentation on  COUNSELING. 1ST YEAR GNM ,COMMUNITY HEALTH NURSINGPresentation on  COUNSELING. 1ST YEAR GNM ,COMMUNITY HEALTH NURSING
Presentation on COUNSELING. 1ST YEAR GNM ,COMMUNITY HEALTH NURSINGKREDASONBANGALORE
 
Drug stability and chemical Kinetics UNIT V
Drug stability and chemical Kinetics UNIT VDrug stability and chemical Kinetics UNIT V
Drug stability and chemical Kinetics UNIT VDr Rakesh Kumar Sharma
 
Artificial Intelligence in Healthcare: Challenges, Risks, Benefits
Artificial Intelligence in Healthcare: Challenges, Risks, BenefitsArtificial Intelligence in Healthcare: Challenges, Risks, Benefits
Artificial Intelligence in Healthcare: Challenges, Risks, BenefitsIris Thiele Isip-Tan
 
"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf
"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf
"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdfDolisha Warbi
 
Artificial Intelligence: Diabetes Management
Artificial Intelligence: Diabetes ManagementArtificial Intelligence: Diabetes Management
Artificial Intelligence: Diabetes ManagementIris Thiele Isip-Tan
 
Anatomy Shelf Notevbhhhhhhhhhhhhhhhs.pdf
Anatomy Shelf Notevbhhhhhhhhhhhhhhhs.pdfAnatomy Shelf Notevbhhhhhhhhhhhhhhhs.pdf
Anatomy Shelf Notevbhhhhhhhhhhhhhhhs.pdfhezamzaki1
 
Experience the Power of Chiropractic in Maui
Experience the Power of Chiropractic in MauiExperience the Power of Chiropractic in Maui
Experience the Power of Chiropractic in MauiCentral Maui Chiropractic
 

Kürzlich hochgeladen (20)

TEST BANK For Neonatal and Pediatric Respiratory Care, 6th Edition by Brian K...
TEST BANK For Neonatal and Pediatric Respiratory Care, 6th Edition by Brian K...TEST BANK For Neonatal and Pediatric Respiratory Care, 6th Edition by Brian K...
TEST BANK For Neonatal and Pediatric Respiratory Care, 6th Edition by Brian K...
 
ARTHRITIS.pptx Prepared by monika gopal Tutor
ARTHRITIS.pptx Prepared  by monika gopal TutorARTHRITIS.pptx Prepared  by monika gopal Tutor
ARTHRITIS.pptx Prepared by monika gopal Tutor
 
LARYNGEAL CANCER.pptx Prepared by Neha Kewat
LARYNGEAL CANCER.pptx  Prepared by Neha KewatLARYNGEAL CANCER.pptx  Prepared by Neha Kewat
LARYNGEAL CANCER.pptx Prepared by Neha Kewat
 
LEUKODYSTROPHY FINAL.pptx sms medical jaipur
LEUKODYSTROPHY FINAL.pptx sms medical jaipurLEUKODYSTROPHY FINAL.pptx sms medical jaipur
LEUKODYSTROPHY FINAL.pptx sms medical jaipur
 
FINAL PROJECT IN EMPOWERMENT TECHNOLOGIES 11
FINAL PROJECT IN EMPOWERMENT TECHNOLOGIES  11FINAL PROJECT IN EMPOWERMENT TECHNOLOGIES  11
FINAL PROJECT IN EMPOWERMENT TECHNOLOGIES 11
 
Painting Rats White Angers Them to No End
Painting Rats White Angers Them to No EndPainting Rats White Angers Them to No End
Painting Rats White Angers Them to No End
 
Toothpaste for bleeding gums and sensitive teeth. Teeth whitening, Mouthwash....
Toothpaste for bleeding gums and sensitive teeth. Teeth whitening, Mouthwash....Toothpaste for bleeding gums and sensitive teeth. Teeth whitening, Mouthwash....
Toothpaste for bleeding gums and sensitive teeth. Teeth whitening, Mouthwash....
 
Annual Training
Annual TrainingAnnual Training
Annual Training
 
Introduction to Evaluation and Skin Benefits
Introduction to Evaluation and Skin BenefitsIntroduction to Evaluation and Skin Benefits
Introduction to Evaluation and Skin Benefits
 
EYE CANCER.pptx prepared by Neha kewat digital learning
EYE CANCER.pptx prepared by  Neha kewat digital learningEYE CANCER.pptx prepared by  Neha kewat digital learning
EYE CANCER.pptx prepared by Neha kewat digital learning
 
Assisted Living Care Residency - PapayaCare
Assisted Living Care Residency - PapayaCareAssisted Living Care Residency - PapayaCare
Assisted Living Care Residency - PapayaCare
 
Eating Disorders in Athletes I Sports Psychology
Eating Disorders in Athletes I Sports PsychologyEating Disorders in Athletes I Sports Psychology
Eating Disorders in Athletes I Sports Psychology
 
The Power of Active listening - Tool in effective communication.pdf
The Power of Active listening - Tool in effective communication.pdfThe Power of Active listening - Tool in effective communication.pdf
The Power of Active listening - Tool in effective communication.pdf
 
Presentation on COUNSELING. 1ST YEAR GNM ,COMMUNITY HEALTH NURSING
Presentation on  COUNSELING. 1ST YEAR GNM ,COMMUNITY HEALTH NURSINGPresentation on  COUNSELING. 1ST YEAR GNM ,COMMUNITY HEALTH NURSING
Presentation on COUNSELING. 1ST YEAR GNM ,COMMUNITY HEALTH NURSING
 
Drug stability and chemical Kinetics UNIT V
Drug stability and chemical Kinetics UNIT VDrug stability and chemical Kinetics UNIT V
Drug stability and chemical Kinetics UNIT V
 
Artificial Intelligence in Healthcare: Challenges, Risks, Benefits
Artificial Intelligence in Healthcare: Challenges, Risks, BenefitsArtificial Intelligence in Healthcare: Challenges, Risks, Benefits
Artificial Intelligence in Healthcare: Challenges, Risks, Benefits
 
"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf
"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf
"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf
 
Artificial Intelligence: Diabetes Management
Artificial Intelligence: Diabetes ManagementArtificial Intelligence: Diabetes Management
Artificial Intelligence: Diabetes Management
 
Anatomy Shelf Notevbhhhhhhhhhhhhhhhs.pdf
Anatomy Shelf Notevbhhhhhhhhhhhhhhhs.pdfAnatomy Shelf Notevbhhhhhhhhhhhhhhhs.pdf
Anatomy Shelf Notevbhhhhhhhhhhhhhhhs.pdf
 
Experience the Power of Chiropractic in Maui
Experience the Power of Chiropractic in MauiExperience the Power of Chiropractic in Maui
Experience the Power of Chiropractic in Maui
 

NICE Decision Outcomes Under the Proposed Valued Based Assessment

  • 1. NICE Decision Outcomes Under the Proposed Value Based Assessment (VBA) Martina Garau PharmAccess Leaders Forum • 19 May 2014 Paris, France
  • 2. Value Based Assessment in the UK 2 • Established in 1962 • Conduct research and provide consultancy services on health economics and related policy issues that affect health care and the life sciences industries • Senior Leadership Team: Adrian Towse, Nancy Devlin, Jon Sussex and Jorge Mestre-Ferrandiz; and a team with diverse and complimentary expertise. • Examples: value-based pricing for molecular diagnostics; multi-criteria decision analysis for valuing orphan medicines; using QALYs in cancer About OHE
  • 3. Value Based Assessment in the UK 3 • Context • Key changes of NICE methods proposed in the value based assessment (VBA) consultation: • ICER threshold/ 'flexible' decision making • Burden of illness • Wider societal impact • Other criteria • Measuring absolute and proportional shortfall • Illustrative examples • Data required for shortfall measurements • Summary points Agenda
  • 4. Value Based Assessment in the UK 4 • ‘Value based pricing’ (VBP) entered UK policy language via the Office of Fair Trading's (OFT) February 2007 report of its investigation into the Pharmaceutical Price Regulation Scheme (PPRS) • One key recommendation: replacement of profit and price controls with 'VBP' • Centralised price setting mechanism determined (or at least heavily influenced) by HTA, assuming: • value = incremental cost effectiveness, and • an explicit threshold can be determined History of value based pricing
  • 5. Value Based Assessment in the UK 5 Andrew Lansley’s pre-election view, 2010
  • 6. Value Based Assessment in the UK 6 1. Pharmacoeconomic evaluation - QALYs 2. 'Burden of illness' 3. 'Therapeutic innovation & improvements' 4. 'Wider societal benefits' 5. Combined via adjusted £/QALY threshold DH proposing 'VBP' for all new medicines (December 2010) December 2010 July 2011
  • 7. Value Based Assessment in the UK 7 • Central role of NICE in value based assessment (VBA) • Consultation set out to amend the current Guide to Methods of Technology Appraisal • ...to end in June 2014 Terms of reference to NICE from DH (July 2013)
  • 8. Value Based Assessment in the UK 8 HTA • Manufacturer sets price then NICE accepts or rejects for reimbursement at that price • Life-extending treatments for patients with <2 years of life expectancy may be eligible for an end-of-life premium PPRS: 1 January 2014 until 31 Dec 2018 • Pre-agreed level of allowed growth rate of UK branded medicine bill for each year of the scheme • Payments in cash once the allowed growth rate is exceeded Current HTA processes and pricing system
  • 9. Distribution of NICE decisions by year NICE has become more binary in its decisions Source: OHE Analysis
  • 10. Distribution of NICE decisions for orphan medicines 75% of orphans are for cancer Source: OHE analysis Orphan drugs are less likely to be recommended by NICE
  • 11. Distribution of NICE decisions for cancer drugs: before and after introduction of end-of -life (EoL) criteria (2009) Post-EoL era is associated with more cancer medicine rejections (Note: not all cancer medicines qualify for EoL criteria) Source: OHE analysis
  • 12. Value Based Assessment in the UK 12 • Context • Key changes of NICE methods proposed in the value based assessment (VBA) consultation: • ICER threshold/ 'flexible' decision making • Burden of illness • Wider societal impact • Other criteria • Measuring absolute and proportional shortfall • Illustrative examples • Data required for shortfall measurements • Summary points Agenda
  • 13. Value Based Assessment in the UK 13 NICE’s current approach £20,000 per QALY £30,000 per QALY £50,000 per QALY Source: NICE Consultation Paper – Value Based Assessment of Health Technologies
  • 14. Value Based Assessment in the UK 14 Proposed 'modifiers' £20,000 per QALY £50,000 per QALY Source: NICE Consultation Paper – Value Based Assessment of Health Technologies
  • 15. Value Based Assessment in the UK 15 • Current threshold: £20k to £30k with discretion above that level (mainly based on end-of-life criteria) • Proposed threshold: £20k with discretion up to £50k • Maximum multiplier (now explicitly indicated) = 2.5 • No indication on how modifiers will be combined • Only specified that their cumulative impact cannot exceed 2.5 New 'flexible' decision making
  • 16. Value Based Assessment in the UK 16 • Aim is to measure the severity of the condition suffered by the patient population • Measured using 'proportional QALY shortfall‘ = 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙 𝑜𝑜𝑜𝑜 𝑄𝑄𝑄𝑄𝑄𝑄𝑄𝑄𝑄𝑄 𝑤𝑤𝑤𝑤𝑤𝑤 𝑤𝑤𝑤𝑤𝑤𝑤𝑤 𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 (𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 𝑎𝑎𝑎𝑎𝑎𝑎) 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛 𝑜𝑜𝑜𝑜 𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟 𝑄𝑄𝑄𝑄𝑄𝑄𝑄𝑄𝑄𝑄 𝑓𝑓𝑓𝑓𝑓𝑓 ℎ𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 (𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔 𝑎𝑎𝑎𝑎𝑎𝑎) • Recognises severity position of patients at end of life (EoL) independently from age  proposal is to exclude EoL criteria • Products that have greater than average proportional shortfall will be assessed against a higher threshold (multiplier > 1) • No guidance for committee on how to apply burden measures to threshold Burden of illness (BoI)
  • 17. Value Based Assessment in the UK 17 • No direct attempt to estimate wider economic impact of a treatment (e.g. 'working days lost') • Instead, NICE proposes to use 'absolute QALY shortfall' as a proxy for patient’s reduced ability to contribute to society = 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙 𝑜𝑜𝑜𝑜 𝑄𝑄𝑄𝑄𝑄𝑄𝑄𝑄𝑄𝑄 𝑤𝑤𝑤𝑤𝑤𝑤 𝑤𝑤𝑤𝑤𝑤𝑤𝑤 𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 (𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔 𝑎𝑎𝑎𝑎𝑎𝑎) • Products that have greater than average absolute shortfall could face a threshold greater than £20k • Again, no guidance as to how this will work in practice Wider societal impact (WSI)
  • 18. Value Based Assessment in the UK 18 • Context • Key changes of NICE methods proposed in the value based assessment (VBA) consultation: • ICER threshold/ 'flexible' decision making • Burden of illness • Wider societal impact • Other criteria • Measuring absolute and proportional shortfall • Illustrative examples • Data required for shortfall measurements • Summary points Agenda
  • 19. Value Based Assessment in the UK 19 • Absolute shortfall (AS) • Captures that society cares about absolute loss of life and quality of life • Based on 'prospective health' (no value on previous health experiences) • Benefits younger populations who have a more QALYs to lose sensitive to age • Proportional shortfall (PS) • Capable of recognising severity of illness in elderly populations • Gives weight to populations facing imminent death • Contains elements of fair innings and prospective health arguments Absolute shortfall vs. proportional shortfall
  • 20. Value Based Assessment in the UK 20 Measuring absolute and proportional shortfall (1) Source: NICE Decision Support Unit critique of DH proposals for BoI
  • 21. Value Based Assessment in the UK 21 Measuring absolute and proportional shortfall (2) • Total potential health (disease-free) going forward = A+B+C+D • Current health prospects (with disease) = D • Absolute shortfall = health lost due to disease = total potential health minus current health prospects = A+B+C • Proportional shortfall = ratio of health lost to total potential health = (A+B+C) / (A+B+C+D)
  • 22. Value Based Assessment in the UK 22 • TA 178: Bevacizumab, sorafenib, sunitinib and temsirolimus for treatment of advanced renal cell carcinoma • Average age of patient = 60 • Expected QALYs without disease = 20.5 • Expected QALYs with disease = 1.24 – Met EoL criteria • Absolute shortfall = 20.5 – 1.24 = 19.26 • Proportional shortfall = 19.26/20.5 = 94% • Both AS and PS significantly greater than average (2.1; 9%)  implies drug would be assessed against ICER threshold > £20k • Proportional shortfall could replicate EoL effect Illustrative example 1 Source: NICE illustrative table http://www.nice.org.uk/getinvolved/currentniceconsultations/MethodsOfTechnologyAppraisalConsultation2014.jsp
  • 23. Value Based Assessment in the UK 23 • TA 217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease • Average age of patient = 77 • Expected QALYs without disease = 8.7 • Expected QALYs with disease = 1.58 • Absolute shortfall = 8.7 – 1.58 = 7.09 • Proportional shortfall = 7.09/8.7 = 82% • Again, both AS and PS significantly greater than average (2.1; 9%)  implies drug would be assessed against ICER threshold > £20k • However, absolute shortfall is lower than previous example, given age of patients Illustrative example 2 Source: NICE illustrative table http://www.nice.org.uk/getinvolved/currentniceconsultations/MethodsOfTechnologyAppraisalConsultation2014.jsp
  • 24. Value Based Assessment in the UK 24 • TA 254: Fingolimod for the treatment of relapsing remitting multiple sclerosis • Average age of patient = 37 • Expected QALYs without disease = 40.7 • Expected QALYs with disease = 3.99 • Absolute shortfall = 40.7 – 3.99 = 36.71 • Proportional shortfall = 36.71/40.7 = 90% • Both AS and PS very high relative to average  implies drug would be assessed against ICER threshold > £20k • AS particularly high – reflects young average age of patients and large health loss with disease Illustrative example 3 Source: NICE illustrative table http://www.nice.org.uk/getinvolved/currentniceconsultations/MethodsOfTechnologyAppraisalConsultation2014.jsp
  • 25. Value Based Assessment in the UK 25 • TA 278: Omalizumab for treatment of severe asthma • Average age of patient = 43 • Expected QALYs without disease = 34.83 • Expected QALYs with disease = 25.31 • Absolute shortfall = 34.83 - 25.31 = 9.52 • Proportional shortfall = 9.52/34.83 = 27% • Again, both AS and PS greater than average (2.1, 9%) but PS lower level than previous examples Illustrative example 4 Source: NICE illustrative table http://www.nice.org.uk/getinvolved/currentniceconsultations/MethodsOfTechnologyAppraisalConsultation2014.jsp
  • 26. Value Based Assessment in the UK 26 Data required for shortfall measurements • DH has calculated BoI for different conditions from a reference dataset developed by the University of York • This presents BoI by the three digit ICD-10 code, aggregated across 16 age/gender categories • Given the broad level of aggregation within the reference dataset, there could be different levels of severity for which it would be important to capture the appropriate BoI • In technology appraisals, it will be appropriate for the company to present the BoI for the specific patient population for the product being appraised
  • 27. Value Based Assessment in the UK 27 • Uncertainty around incremental cost effectiveness ratio (ICER): • Penalties for uncertainty around the ICER now only apply for routine use and where ICER is 'very uncertain' rather than 'less certain' • Health-related quality of life (HRQoL) inadequately captured: • No changes proposed • Innovative nature of technology: • Now includes reference to 'a step change in the management of a condition' • Non-health objectives of the NHS: • No changes proposed Other modifiers
  • 28. Value Based Assessment in the UK 28 • Cost savings outside the NHS and non-health benefits (e.g. productivity) can now be considered even when not specifically requested by the Department of Health in non-reference case Other changes to the methods guide
  • 29. Value Based Assessment in the UK 29 • EoL criteria replaced by BoI • Proposed threshold = £20k, with discretion up to £50k for products that qualify for modifiers • No guidance on BoI and WSI weights • No guidance on how other factors will be quantified and aggregated • It is likely that NICE will continue adopting a deliberative, rather than an algorithmic, approach to making decisions • An evolutionary, not revolutionary change • For most products, outcomes will probably be similar to those under the old system Summary of key points
  • 30. Value Based Assessment in the UK 30 Paul Barnsley for his work on absolute and proportional shortfall (see OHE note on the NICE website) Acknowledgements
  • 31. Value Based Assessment in the UK 31 About OHE To enquire about additional information and analyses, please contact Martina Garau at mgarau@ohe.org To keep up with the latest news and research, subscribe to our blog, OHE News. Follow us on Twitter @OHENews, LinkedIn and SlideShare. The Office of Health Economics is a research and consulting organisation that has been providing specialised research, analysis and expertise on a range of health care and life sciences issues and topics for more than 50 years. OHE’s publications may be downloaded free of charge for registered users of its website. Office of Health Economics Southside, 7th Floor 105 Victoria Street London SW1E 6QT United Kingdom +44 20 7747 8850 www.ohe.org